Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

Slides:

Advertisements

Similar presentations

Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.

Advertisements

Pathological alterations in idiopathic pulmonary fibrosis (IPF).

Changes in high-resolution computed tomography (HRCT) pattern over time. a) Idiopathic pulmonary fibrosis (IPF), increased specificity over time. Changes.

Longitudinal imaging after initial diagnosis

Flow diagram of the systematic research method for detecting matching microRNAs (miRNAs) in systemic sclerosis (SSc) and idiopathic pulmonary fibrosis.

High-resolution computed tomography (HRCT) features of interstitial lung abnormalities. a) HRCT of a 56-year-old patient whose mother died of idiopathic.

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Radiology assessment of pulmonary amyloidosis

Comparative expression of discoidin domain receptors (DDRs) between healthy lung tissues and those from different types of interstitial lung disease (ILD):

A) Chest radiograph, b) multislice computed tomography angiography, c) three-dimensional magnetic resonance angiography, d) perfusion scintigraphy and.

Schematic representation of the potential clinical courses of idiopathic pulmonary fibrosis. Schematic representation of the potential clinical courses.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

a) Chest radiograph showing bilateral coarse interstitial shadowing

Axial computed tomography (CT) images a) at baseline and b) at a 12-month follow-up scan, in a patient with idiopathic pulmonary fibrosis (IPF). b) Note.

A) Low magnification histopathological biopsy showing typical features of usual interstitial pneumonia pattern with a heterogeneous appearance and areas.

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

Smoking cessation rate as point prevalence quit rate from year 1 to 5 in the Lung Health Study with 5,587 chronic obstructive pulmonary disease patients.

Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)

Phosphorylation levels of discoidin domain receptor (DDR)2.

Nonspecific interstitial pneumonia fibrosing pattern in a case of connective tissue disease. a) The alveolar walls are thickened by interstitial fibrosis.

Unclassifiable interstitial fibrosis.

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Pattern high-resolution computed tomography consistent with nonspecific interstitial pneumonia in a patient with histological diagnosis of usual interstitial.

Evaluation of acute symptoms

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.

Evaluation of complications.

Prevalence of different aetiologies of pulmonary hypertension (PH) in the paediatric population (results from national registries and paediatric cohorts).

Elastic staining of paraffin-embedded lung tissue.

Simplified diagram of the multidisciplinary process to diagnose interstitial lung disease, including a clinician, radiologist, pathologist and also a geneticist:

Proteinase activated receptor-1 expression in a) weak immunostaining in normal lung tissue, b) intense immunostaining in idiopathic pulmonary fibrosis,

A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

Incidence of chronic obstructive pulmonary disease according to the history of chronic cough/phlegm. Incidence of chronic obstructive pulmonary disease.

Model for the association between pathological features, physiological alterations and their association with pathological and clinical features. Model.

Significance of the principal genetic variants associated with familial pulmonary fibrosis by their strength and frequency. Significance of the principal.

Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.

Transbronchial cryobiopsy (TBCx)

The alveolar compartment in idiopathic pulmonary fibrosis (IPF).

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

A) 8-isoprostane levels in exhaled breath condensate in smokers with chronic obstructive pulmonary disease (COPD). *: p

This schematic view of the morpho-functional unit of the lung (alveolus) depicts the main differences in cellular composition in idiopathic pulmonary fibrosis.

The effect of inhaled tiotropium (18 μg once daily) on the improvement in treadmill exercise endurance time in patients with chronic obstructive pulmonary.

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

A) Small pulmonary arteries within a fibrotic area (usual interstitial pneumonia lung). a) Small pulmonary arteries within a fibrotic area (usual interstitial.

Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life (HRQoL) measures versus the normal population and other.

Proportion of participants with access to a, b) a radiologist and c, d) a pathologist experienced in interstitial lung diseases to discuss cases of suspected.

Comorbidities/associated conditions/complications assessed in patients diagnosed with idiopathic pulmonary fibrosis (IPF) in the 2013 Advancing IPF Research.

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Usual interstitial pneumonia pattern in two patients with idiopathic pulmonary fibrosis. a) At low magnification, subpleural/paraseptal scars obscuring.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Clinical findings in patients with chronic obstructive pulmonary disease according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD)

Procedure for the diagnosis of interstitial lung diseases.

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Investigation of suspected idiopathic pulmonary fibrosis: multidisciplinary team (MDT) discussion is a key component of the diagnostic pathway. Investigation.

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Cellular players and molecules in idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease. Cellular players and.

Possible mechanisms of famillial idiopathic interstitial pneumonia leading to lung fibrosis involves apoptosis caused mainly through chronic endoplasmic.

Hyperplastic alveolar epithelial type II cells show severe endoplasmic reticulum stress and consecutive apoptosis. Hyperplastic alveolar epithelial type.

Interventional bronchoscopic and surgical treatments for chronic obstructive pulmonary disease (COPD). Interventional bronchoscopic and surgical treatments.

A) Dyspnoea response at rest, iso-time, and peak exercise in 20 patients with fibrotic interstitial lung disease during constant work-rate cycle exercise.

Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF).

High-resolution computed tomography images of smoking-related interstitial lung diseases (ILDs). a) Pulmonary Langerhans cell histiocytosis, b) respiratory.

A) Smokers’ macrophages show a fine, golden haemosiderin cytoplasmic pigment; b) in respiratory bronchiolitis (RB), smokers’ macrophages are located in.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with biopsy-proven idiopathic pulmonary fibrosis. ·········: treatment with bosentan, ––––: placebo. a) Hazard... Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with biopsy-proven idiopathic pulmonary fibrosis. ·········: treatment with bosentan, ––––: placebo. a) Hazard ratio (95% confidence interval): 0.613 (0.328–1.144); p = 0.119. b) Hazard ratio (95% confidence interval): 0.315 (0.126–0.789); p = 0.009. K. K. Brown, and A. U. Wells Eur Respir Rev 2008;17:116-122 ©2008 by European Respiratory Society